| Date | Title | Description |
| 11.08.2016 | Quintiles uses Solution Design Studio in journey to integrate digital tech with clinical trials | “I probably can’t go into details for specific customers, but we’re really close,” said Shelby Burdick, global head of the Solution Design Studio, in a phone interview.
The Solution Design Studio opened May 17 at the company’s campus in Res... |
| 03.08.2016 | 3i generates £73m from the sale of its remaining shares in Quintiles | 3i Group plc (“3i”) announces that 3i, and funds managed by 3i, have sold all of their remaining shares in Quintiles Transnational (“Quintiles” or “the Company”).
3i Group plc (“3i”) announces that 3i, and funds managed by 3i, have sold al... |
| 27.06.2016 | Morning Read: Speculating on Brexit’s impact on UK startups | Hearing aid developer Earlens Corp. made the first close of a $51 million Series C preferred stock financing led by Vertex Healthcare. Other investors taking part in the round included Cochlear, a developer of advanced implantable hearing t... |
| 03.06.2016 | Two new clinical trial recruitment methods harness the power of IT | One, a smartphone app, was developed by Dr. Peter Elkin, a biomedical informatics professor at the University at Buffalo. He unveiled the app Thursday at the Information Technology in Academic Medicine conference in Toronto. He developed th... |
| 07.05.2016 | M&A roundup - week ending 5/7/16 | Adobe bought Livefyre; LinkedIn acquired Run Hop; Pinterest purchased URX
Video-sharing website Vimeo acquired VHX, a platform that allows video creators sell their content from their own websites. No financial terms of the deal were disclo... |
| 04.05.2016 | IMS Health, Quintiles to Merge in $9B Deal: 10 Things To Know | Healthcare technology provider IMS Health Holdings announced it will merge with biopharma research contract provider Quintiles Transnational Holding in a deal valued at $9 billion. The merged company will be named Quintiles IMS Holdings, In... |
| 01.12.2015 | These pharma and digital health collaborations are poised to transform clinical trials | This post has been updated from an earlier version
Propeller Health added a second big pharma partner with its GlaxoSmithKline research and development deal to produce sensors for the company’s Ellipta dry powder inhaler, according to a com... |
| 29.05.2015 | Johnson and Johnson accepts $2B offer for vascular medical device producer, Teva reaches settlement (Morning Read) | Otsuka Pharmaceutical Co Ltd lost a lawsuit challenging the U.S. Food and Drug Administration’s decision allowing other companies to make generic versions of the it’s antipsychotic drug, Abilify. Because the FDA typically grants years of ex... |
| 16.10.2013 | Where is the cloud comfort zone for pharma and biotech companies? | In addition to sales teams, shared databases are also helping drug developers identify principal investigators. Principal investigator contact details used to be considered proprietary information. But studies from the likes of Quintiles fo... |
| 09.05.2013 | Q is for Quintiles: CRO picked good time to return to the public markets | “We think the firm’s unparalleled size and exposure outfit it with a narrow economic moat and the strongest competitive advantages in the CRO industry. Drugmakers’ increased use of outsourcing and the emerging strategic partnership model ar... |
| 15.02.2013 | 5 interesting things from Quintiles IPO filing | When the rumors of an IPO were just beginning to rev up, Jessica Gladstone, a senior analyst at Moody’s told Bloomberg: “I view the fact that they have a new CEO now as potentially a sign that they’re preparing their next leg of growth or n... |
| 04.02.2013 | FDA hearing questions how to develop fast lane for drug development for unmet medical needs | Design preregistration trials using data from de-identified electronic medical records to get real-world incidence and event rates.
Make use of genetic testing and testing with biomarkers to identify patient populations.
Break down silos be... |
| 13.07.2012 | Quintiles software deal with Allscripts seeks to clear up clinical trial bottlenecks | One part of Quintiles collaboration with Allscripts is to narrow the patient profile, said Gavin Nichols, Quintiles vice president, research and development innovation, IT, in a phone interview. For example, instead of looking for a rheumat... |
| 06.03.2012 | To catch a CRO – details Dateline’s pharma expose doesn’t quite capture | If you missed the broadcast, it’s available online. Hansen, posing as CEO of fictitious pharma Malum Kinetics, goes to India to find a CRO to conduct clinical trials on a compound that is chemically identical to Vioxx, the Merck (NYSE:MRK) ... |
| 01.03.2012 | INC Research tops CRO quality ranking as M&A shapes pharma outsourcing | Before acquiring Kendle last year, INC was a mid-sized CRO whose size and pharmaceutical outsourcing service offerings fell well short of the largest CROs such as Quintiles and Parexel. Raleigh, North Carolina-based INC’s service quality me... |
| 29.02.2012 | Icon’s PriceSpective acquisition adds drug price expertise to CRO’s portfolio | The PriceSpective deal follows completion of the BeijingWits Medical Consulting acquisition, which adds to Icon’s presence in China. Much of the CRO acquisition activity of the last year has been driven by the desire of large CROs to add sp... |
| 24.02.2012 | Russian Venture Company Biofund and Quintiles to Invest in Clinical Development Services | Investment firm Russian Venture Company Biofund and Quintiles, a Moscow-based biopharmaceutical services company, have signed a deal to support expansion of clinical development services companies within the Russian Federation.
The partners... |
| 11.01.2012 | CRO industry rebound hinges on big pharma partnerships, Morningstar says | “We expect growth in the CRO industry to continue accelerating into 2012 and the rise of the strategic partnership model should concentrate these benefits in the hands of a select group of narrow-moat providers,” wrote Lauren Migliore, a Mo... |
| 03.01.2012 | Quintiles forms digital unit to boost online clinical trials recruitment | “We’ve had patient recruitment services before but we haven’t had a specifically digital approach,” company spokesman Phil Bridges said.
MediGuard.org, launched by Quintiles in 2007, is a drug-monitoring service that provides its 2.5 millio... |
| 23.12.2011 | A clinical research organization wish list for Christmas (and new year) | A strategic partner: The biggest CROs such as, Quintiles, PPD, and Covance (NYSE:CVD) are increasingly moving toward strategic partnerships, making them a “preferred provider” of services. In these arrangements, a pharma will contract with ... |
| 13.12.2011 | Quintiles launches new China CRO Kun Tuo | Quintiles recently exited a piece of the Asia-Pacific market with the sale of its minority stake in Invida, a drug commercialization joint venture based in Singapore. Invida, which was acquired by Italian pharmaceutical services provider Me... |
| 24.11.2011 | TrialBee could save lives by bringing drugs to market faster | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Big pharma still uses manual methods to recruit p... |
| 24.11.2011 | TrialBee could save lives by bringing drugs to market faster | Big pharma still uses manual methods to recruit participants for drug trials, and that costs the industry money. Lots of money. The pharma industry loses $4.2 billion per year due to drug trial delays and $250K in lost sales per day that a ... |
| 23.11.2011 | Hospira commits $375M to make troubled N.C. plant FDA compliant | The FDA sent Hospira an April 2010 warning letter that contained quality assurance and compliance concerns for the Rocky Mount plant. Hospira temporarily shut down the plant to deal with those concerns. But problems persisted. A June inspec... |
| 26.10.2011 | Quintiles boosts early phase capabilities with Advion acquisition | Drug analysis provided by Advion includes pharmacokinetics (PK), the study of what the body does to a drug, as well as pharmacodynamics (PD), the study of what the drug does to the body. This analysis gives pharmaceutical companies early in... |
| 19.10.2011 | Quintiles acquires VCG to build drug commercialization capabilities | “The addition of VCG allows us to strengthen our capabilities in that area,” Bridges said.
Privately held VCG & Associates was founded in 2003 and is based in Holliston, Massachusetts. VCG BIO operates from Cave Creek, Arizona. Financia... |
| 22.09.2011 | Quintiles names Teleflex executive to worldwide controller post | Quintiles has named a former executive from medical devices company Teleflex (NYSE:TFX) to a top financial position at the pharmaceutical services firm.
Charles Williams will serve as worldwide controller for Durham, North Carolina-based Qu... |
| 16.08.2011 | PPD in ‘exclusive talks’ with Carlyle Group about M&A deal, reports say | Several private equity firms expressed interest, including Blackstone Group (NYSE:BX), KKR & Co. and Hellman & Friedman, two unnamed sources told Bloomberg. Carlyle’s bid topped all of them. Bids were between $33 and $38 a share — a... |
| 12.08.2011 | Vision-Sciences puts Cynthia Ansari in the corner office | Personnel Moves | Endoscopic device maker Vision-Sciences Inc. (NSDQ:VSCI) announced that they had found someone to take over the corner office, naming Cynthia Ansari CEO.
Ansari steps will take over the top seat from interim CEO Warren Bielke, who has steer... |
| 26.07.2011 | Is private equity interested in buying PPD? | PPD (NYSE:PPDI) released second-quarter earnings today and in the conference call to follow Wednesday morning, I would bet on at least two questions analysts will pose to management of the North Carolina clinical research organization:
How ... |
| 18.07.2011 | PPD for sale? Management says no ‘combination’ talks happening | Talk of whether PPD (NYSE:PPDI) is for sale has prompted the clinical research organization to publicly state it not in talks with any other CRO regarding a merger or acquisition.
But Wilmington, North Carolina-based PPD did say that its bo... |
| 13.07.2011 | Pharmas need new innovation strategy to steer clear of patent cliff, report says | Only 47 percent of executives said their company’s R&D model was capable of meeting their company’s needs.
49 percent rated their company’s overall innovation strategy as just moderately effective at best.
And yet, just 54 percent consi... |
| 14.06.2011 | Mid-sized CROs perform as good or better than larger ones, survey says | Kevin Olson, CEO of ISR, said that the survey responses and data do not show why mid-sized CROs as a whole scored better than larger ones. But he theorizes the smaller CROs might be seen as offering better service because while they may not... |
| 05.06.2011 | INC Research buys Australian CRO Trident to boost global presence | INC Research, still completing its $232 million acquisition of clinical research organization Kendle International Inc. (NSDQ:KNDL), bought yet another CRO to add to its global footprint.
Raleigh, N. C.-based INC Research acquired Australia... |
| 02.06.2011 | INC Research buys Australian CRO Trident to boost global presence | “Trident is an important piece in our strategy to build a sustainable CRO business that both satisfies and anticipates the global drug development needs of our customers,” INC Research CEO James Ogle said in a statement.
Adelaide, Australia... |
| 24.05.2011 | Quintiles ‘New Health’ survey hints at coming healthcare industry changes | For one, 81 percent of biopharma executives surveyed said patients aren’t effectively improving their lifestyle behavior to reduce health risks. But just 33 percent of patients agreed with that statement. A question about personalized medic... |
| 18.05.2011 | Clinipace acquires Swiss firm PFC to build global CRO presence | Zurich, Switzerland-based PFC has offices in Germany, Israel and India. The CRO focuses on drug and medical development, as well as regulatory consulting. The announcement of the PFC acquisition follows financing activity last week in which... |
| 17.05.2011 | CRO Novella picks Quintiles, PPD veteran to lead business development | CEO Richard Staub said he knows Dyer from their time together working at PPD, where Dyer built up experience in global business development. Dyer will take the reins of Novella’s business development team, which had previously reported to S... |
| 13.05.2011 | Quintiles aims to restructure debt with $2 billion in credit | Funding roundup | Quintiles is resuming its plans to raise more than $2 billion in bank financing.
The Durham, N.C.-based, contract research organization is planning to enter into a new $2.2 billion credit facility, with proceeds from the borrowed funding be... |
| 10.05.2011 | Quintiles dusts off plans for $2 billion in bank financing | But the company later that month postponed the financing plans explaining that the favorable terms were no longer available due to global credit market conditions. The company now says that the bank financing will provide it with more favor... |
| 14.04.2011 | Breakthrough breast cancer trial receives $2.6M from Quintiles | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 24.03.2011 | Quintiles spikes $2.4 billion financing move | Quintiles’ plans for $2.43 billion in bank financing have been put off indefinitely due to what the clinical research organization now describes as “recent unfavorable global credit market conditions.”
In postponing the financing, the Durha... |
| 22.03.2011 | Quintiles cancels $2.43B financing plan, cites global market conditions | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| 08.03.2011 | Quintiles raising $2.43B for refinancing and future deals | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 03.03.2011 | INC Research brings on new CFO, aims to crack CRO industry’s top 5 | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| 19.01.2011 | Quintiles layoffs consistent with CRO industry | Quintiles is laying off workers again. The Durham, North Carolina-based clinical research organization is laying off workers in a "small employee action," according to LocalTechWire.
Quintiles, a privately held company, isn’t disc... |
| 28.07.2009 | Kendle International realigns executives to drive innovation, productivity, efficiency | Bergen led Kendle’s recent enterprise resource planning (ERP) initiative, which is winding to a close. It was the largest initiative in the company’s history and is expected to yield benefits such as streamlined global processes, enhanced ... |
| 14.11.2007 | Life sciences briefing: Wednesday, Nov. 14, 2007 | Featured companies: Advanced Bio-Surfaces, Ambit Biosciences, EnteroMedics, Molecular Vision, Skyline Ventures
UPDATED: Expanded items on Skyline Ventures, Ambit, and Molecular Vision, and moved EnteroMedics to a new item here.
Skyline Vent... |
| 15.12.2003 | Meridica extends its Xcelodose (TM) showcasing agreement with Quintiles | Meridica extends its Xcelodose (TM) showcasing agreement with Quintiles
15-12-2003
Meridica Limited, the Cambridge, UK-based drug delivery company, has announced the renewal of its Showcasing Agreement for Xcelodose(TM), its unique powder m... |
| - | Quintiles cancels $2.43B financing plan, cites global market conditions | Quintiles‘ plans for $2.425 billion in bank financing have been put off indefinitely due to what the clinical research organization now describes as “recent unfavorable global credit market conditions.”
In postponing the financing, the Durh... |
| - | CRO industry rebound hinges on big pharma partnerships, Morningstar says | Clinical research organizations are on a rebound and the CRO industry is poised for 2012 growth led by the largest CROs exercising deals with large pharmaceutical companies, according to a new report by investment research firm Morningstar.... |
| - | Quintiles raising $2.43B for refinancing and future deals | Quintiles plans to raise $2.43 billion that the clinical research organization will use to refinance existing debt and apply to future deals that could include acquisitions and new partnerships.
In securing the bank financing, the Durham, N... |
| - | Quintiles names Teleflex executive to worldwide controller post | Quintiles has named a former executive from medical devices company Teleflex (NYSE:TFX) to a top financial position at the pharmaceutical services firm.
Charles Williams will serve as worldwide controller for Durham, North Carolina-based Qu... |
| - | Q is for Quintiles: CRO picked good time to return to the public markets | [Update] Contract research organization Quintiles returned to the public markets today, trading on the NYSE under the stock symbol Q. It raised $947 million after it was priced at $40. Although the share price initially rose 9 percent after... |
| - | These pharma and digital health collaborations are poised to transform clinical trials | This post has been updated from an earlier version
Propeller Health added a second big pharma partner with its GlaxoSmithKline research and development deal to produce sensors for the company’s Ellipta dry powder inhaler, according to a com... |
| - | FDA hearing questions how to develop fast lane for drug development for unmet medical needs | Drug development takes a long time and costs a huge amount of money to meet the standards of the U.S. Food and Drug Administration. But the FDA is holding a hearing today and tomorrow to pick the brains of industry experts, and see how a sp... |
| - | PPD for sale? Management says no ‘combination’ talks happening | Talk of whether PPD (NYSE:PPDI) is for sale has prompted the clinical research organization to publicly state it not in talks with any other CRO regarding a merger or acquisition.
But Wilmington, North Carolina-based PPD did say that its bo... |
| - | CRO Novella picks Quintiles, PPD veteran to lead business development | Clinical research organization Novella Clinical has hired a veteran of both Quintiles and PPD into its executive ranks as the company charts a global growth plan.
Nick Dyer is the new executive vice president of global business development ... |
| - | Quintiles launches new China CRO Kun Tuo | Quintiles is expanding its reach in the Asia-Pacific region with the launch of Kun Tuo, a new contract research organization in China.
The new CRO will serve pharmaceutical companies in China as well as multinational biopharma companies tha... |
| - | Icon’s PriceSpective acquisition adds drug price expertise to CRO’s portfolio | Count Icon (NASDAQ:ICLR) among the clinical research organizations continuing the industry M&A activity.
The Ireland-based CRO has acquired PriceSpective, a CRO with a consulting focus and expertise in drug pricing. Icon didn’t disclose... |
| - | INC Research buys Australian CRO Trident to boost global presence | INC Research, still completing its $232 million acquisition of clinical research organization Kendle (NASDAQ:KNDL) , has bought yet another CRO to add to its global footprint.
Raleigh, North Carolina-based INC Research has acquired Australi... |
| - | To catch a CRO – details Dateline’s pharma expose doesn’t quite capture | If you don’t know Dateline NBC‘s Chris Hansen by name or even by face, you know him by formula: hidden camera reporting that offers an inside look at people saying and doing things they would otherwise keep under wraps.
Hansen’s technique i... |
| - | Johnson and Johnson accepts $2B offer for vascular medical device producer, Teva reaches settlement (Morning Read) | TOP STORIES
Johnson & Johnson (NYSE: JNJ) has accepted Cardinal Health‘s $2 billion offer to acquire vascular medical device producer, Cordis.
Teva reached a $1.2 billion settlement with the Federal Trade Commission over
claims that Cep... |
| - | Breakthrough breast cancer trial receives $2.6M from Quintiles | Quintiles, which has run countless clinical trials for cancer drug candidates, is taking a turn as a financial supporter for a study with a $2.6 million contribution directed toward a breakthrough breast cancer trial.
I-SPY 2, is a clinical... |
| - | Hospira commits $375M to make troubled N.C. plant FDA compliant | Hospira (NYSE:HSP) plans to spend up to $375 million over the next three years to bring its manufacturing facilities into regulatory compliance, the bulk of it going to a North Carolina plant saddled under heavy regulatory scrutiny for much... |
| - | Quintiles forms digital unit to boost online clinical trials recruitment | Quintiles is expanding its healthcare social media reach with the launch of a new digital business unit that will help the company recruit patients for clinical trials.
The new Digital Patient unit builds on the clinical research organizati... |
| - | Quintiles boosts early phase capabilities with Advion acquisition | Quintiles‘ M&A activity continues as the company announced it will acquire clinical research organization Advion BioServices — Quintiles’ third deal in the last week.
Advion provides bioanalytical lab services that help pharmaceutical c... |
| - | Kendle International realigns executives to drive innovation, productivity, efficiency | CINCINNATI, Ohio — Kendle International Inc. on Tuesday announced an executive realignment as the latest in a series of efforts to better position the company as a top-tier, global contract research organization.
The company that provi... |
| - | Quintiles ‘New Health’ survey hints at coming healthcare industry changes | Quintiles wanted to find out what healthcare stakeholders think about the industry, so the company did the natural thing: It conducted a survey.
For two months this winter, a company hired by Quintiles called up biopharmaceutical executives... |
| - | 5 interesting things from Quintiles IPO filing | The rumors, it seems were true after all. In an environment where initial public offerings by life science companies have all but dried up, Quintiles, the largest contract research organization, has filed documents with the Securities and E... |
| - | Mid-sized CROs perform as good or better than larger ones, survey says | Pharmaceutical companies evaluating which clinical research organizations to work with might want to take note that perhaps size doesn’t matter.
As a group, mid-sized CROs performed quite well or even better than their larger counterparts a... |
| - | Quintiles acquires VCG to build drug commercialization capabilities | Quintiles has acquired pharmaceutical commercialization and marketing firm VCG & Associates and its subsidiary, VCG Bio, in a move to bolster the company’s drug capabilities to bring new drugs to market.
Durham, North Carolina based Qui... |
| - | Quintiles dusts off plans for $2 billion in bank financing | Quintiles is resuming its plans to raise more than $2 billion in bank financing.
The Durham, North Carolina, clinical research organization announced late Tuesday that it would enter into a new $2.2 billion credit facility, with proceeds fr... |
| - | PPD in ‘exclusive talks’ with Carlyle Group about M&A deal, reports say | Clinical research organization PPD (NYSE:PPDI) is talking with private equity firm The Carlyle Group about an M&A deal.
Bloomberg News reports that Carlyle is in exclusive talks to possibly acquire Wilmington, North Carolina-based PPD, ... |
| - | Morning Read: Speculating on Brexit’s impact on UK startups | TOP STORIES
As the world comes to grips with the UK referendum favoring an exit from the European Union, the discussion shifts to startups there and how the vote will affect them. There’s no doubt that the uncertainty will have a chilling e... |
| - | Is private equity interested in buying PPD? | PPD (NYSE:PPDI) released second-quarter earnings today and in the conference call to follow Wednesday morning, I would bet on at least two questions analysts will pose to management of the North Carolina clinical research organization:
How ... |
| - | Two new clinical trial recruitment methods harness the power of IT | Participants in Science app
What if you set up a clinical trial and nobody signed up? That’s an all-too-common problem for many researchers; only 3 percent of patients with cancer, for instance, sign up for a clinical trial and up to 60 per... |
| - | Where is the cloud comfort zone for pharma and biotech companies? | If any sector gets more flack for being slow to adopt innovative IT than healthcare, it’s the pharmaceutical industry. Yet, as companies have been forced to find new ways to streamline work flows and reduce costs, many are finding that some... |
| - | INC Research tops CRO quality ranking as M&A shapes pharma outsourcing | Among clinical research organizations, INC Research is not the biggest, but by at least one measure, it stands out as the best.
INC received the best service quality scores in the annual CRO quality benchmarking study conducted by Industry ... |
| - | Quintiles software deal with Allscripts seeks to clear up clinical trial bottlenecks | Quintiles is collaborating with electronic health records firm Allscripts Healthcare Solutions (NASDAQ:MDRX) to develop software to streamline the process of setting up and recruiting for clinical trials in a move that could cut the cost of... |
| - | Clinipace acquires Swiss firm PFC to build global CRO presence | Clinical research organization Clinipace Worldwide has acquired Swiss company PFC Pharma Focus in a move that extends Clinipace’s global presence.
The acquisition is the third in 18 months and the second this year for Morrisville, North Car... |
| - | INC Research brings on new CFO, aims to crack CRO industry’s top 5 | INC Research, a North Carolina clinical research organization, has hired its new chief financial officer from the ranks of a fellow North Carolina company as it charts a growth course to make the Raleigh firm one of the biggest players in t... |
| - | Quintiles uses Solution Design Studio in journey to integrate digital tech with clinical trials | Solution Design Studio mannequin wearing Google Glass and Fitbit.
Smart phones aren’t just for playing hours-long games of Pokemon Go. Along with fitness trackers, smart watches, and virtual reality headsets, the newest digital tools are th... |
| - | Pharmas need new innovation strategy to steer clear of patent cliff, report says | The patent cliff facing pharmaceutical companies has been staring down the industry for years, but even as companies now watch former blockbuster drugs tumble off its edge, many of those businesses still remain ill equipped to kick-start th... |
| - | A clinical research organization wish list for Christmas (and new year) | North Carolina clinical research organization PPD got an early Christmas present with the completion of its $3.9 billion acquisition by private equity firms The Carlyle Group and Hellman & Friedman.
Talks about the CRO acquisition began... |